---
id: "2026-10-08-isomorphic-labs-talks-40b-valuation"
url: "https://postcutoff.com/e/2026-10-08-isomorphic-labs-talks-40b-valuation/"
as_of: "2026-10-09T19:24:00+02:00"
date: "2026-10-08"
date_precision: day
category: business
importance: 2
confidence: medium
status: [Partly confirmed]
sources: 3
editor: Adam Bicz
human_review: null
version: null
---

As of: 2026-10-09 19:24 CEST.
Researched and written by AI agents (Claude Opus 5.5 in Claude Code). Human editor: Adam Bicz.
Canonical page: https://postcutoff.com/e/2026-10-08-isomorphic-labs-talks-40b-valuation/

# Isomorphic Labs in early talks to raise at a $40B–$50B valuation, five months after its $2.1B round

Bloomberg reported on Oct 8, 2026 that Alphabet's AI drug-discovery company Isomorphic Labs, spun out of Google DeepMind, is in early talks to raise new money at a valuation of at least $40B, possibly up to $50B (SiliconANGLE). That is less than five months after its $2.1B Series B. It still has no AI-designed drug in human trials; first trials are targeted for the end of 2026.

## Key facts
- Valuation sought: at least $40B (Bloomberg, Oct 8, 2026), possibly as much as $50B (SiliconANGLE); amount and investors not reported; talks early and could change
- Previous round: $2.1B Series B led by Thrive Capital, May 2026
- Partnerships: deals worth nearly $3B with Eli Lilly and Novartis (2024) and a Johnson & Johnson collaboration (January 2026)
- No Isomorphic-designed drug has been dosed in humans yet; first trials are expected by end-2026 (Tech Funding News)

## What happened

On October 8, 2026, Bloomberg reported that Isomorphic Labs is in early talks with investors at a valuation of at least $40 billion. Isomorphic
is the Alphabet company that turns DeepMind's AlphaFold-line research into drug design. SiliconANGLE put the possible range at up to $50 billion.
The round is not closed, and neither the amount nor the investors were reported.

## Why it matters

A roughly tenfold jump in valuation before any clinical data shows how much investors now pay for AI-for-science platforms. Isomorphic's
promised first human trials by the end of 2026 are the near-term test.

## Your AI and this story

- GPT-6 Astra (training cutoff April 2026): 161 days after its cutoff
- Claude Opus 5.5 (training cutoff June 2026): 100 days after its cutoff
- Gemini 3.8 Flash (training cutoff March 2026): 191 days after its cutoff
- Grok 4.7 (training cutoff May 2026): 130 days after its cutoff

## Sources

1. [Bloomberg: Alphabet's Isomorphic Labs in funding talks for at least $40 billion value](https://www.bloomberg.com/news/articles/2026-10-08/alphabet-s-isomorphic-labs-in-funding-talks-for-at-least-40-billion-value) (bloomberg.com, press)
2. [SiliconANGLE: Alphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation](https://siliconangle.com/2026/10/08/alphabet-spinoff-isomorphic-labs-reportedly-raising-funding-at-up-to-50b-valuation/) (siliconangle.com, press)
3. [Tech Funding News: Isomorphic Labs eyes $40B valuation less than five months after $2.1B round](https://techfundingnews.com/deepmind-spinout-isomorphic-labs-eyes-40b-valuation-less-than-five-months-after-2-1b-round-report/) (techfundingnews.com, press)

## Changes

- 2026-10-09 (filed): Created

## Related

- 2026-05-12: [Isomorphic Labs raises $2.1B Series B](https://postcutoff.com/e/2026-05-12-isomorphic-labs-series-b/index.md)
- 2026-02-10: [Isomorphic Labs unveils IsoDDE drug-discovery engine, hailed as 'an AlphaFold 4'](https://postcutoff.com/e/2026-02-10-isomorphic-isodde/index.md)